Cargando…

Cardiovascular Profile of Patients with Type 2 Diabetes in France Based on REWIND CVOT Inclusion Criteria: A Real-World Retrospective Study

INTRODUCTION: The REWIND study demonstrated a cardiovascular (CV) benefit of dulaglutide treatment in patients with type 2 diabetes (T2D) with or without established cardiovascular disease (CVD). The current study aims to describe similarities and differences between characteristics of patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dib, Anne, Chartier, Florence, Ihle, Katharina, Jamonneau, Isabelle, Ludwig, Lisa, Darmon, Patrice
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873332/ https://www.ncbi.nlm.nih.gov/pubmed/35034340 http://dx.doi.org/10.1007/s13300-021-01200-0

Ejemplares similares

RP rewind
Publicado: (2020)

REWIND Diabetes for Octogenarians
por: Geberhiwot, Tarekegn
Publicado: (2021)

Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide
por: Verma, Subodh, et al.
Publicado: (2021)

Report from the 5th cardiovascular outcome trial (CVOT) summit
por: Schnell, Oliver, et al.
Publicado: (2020)

Report from the CVOT Summit 2020: new cardiovascular and renal outcomes
por: Schnell, Oliver, et al.
Publicado: (2021)

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
por: Schnell, Oliver, et al.
Publicado: (2023)

Unwinding and Rewinding: Double Faces of Helicase?
por: Wu, Yuliang
Publicado: (2012)

Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes
por: Schnell, Oliver, et al.
Publicado: (2022)

Rewinding the waves: tracking underwater signals to their source
por: Kadri, Usama, et al.
Publicado: (2017)

Mistreatment in Residency: Intervening With the REWIND Communication Tool
por: Pang, Joyce, et al.
Publicado: (2022)

Levorphanol: Rewinding an Old, Bygone Multimodal Opioid Analgesic!
por: Nair, Abhijit S, et al.
Publicado: (2019)

The reconsolidation using rewind study (RETURN): trial protocol
por: Astill Wright, Laurence, et al.
Publicado: (2021)

27 September 2013: Fast forward and rewind to our Origins
por: Antonella Del Rosso
Publicado: (2013)

Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
por: Konig, Manige, et al.
Publicado: (2021)

Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs
por: Schernthaner, Guntram, et al.
Publicado: (2019)

OR30-06 Assessment of Dulaglutide Safety in Older Patient Populations in Rewind
por: Konig, Manige, et al.
Publicado: (2020)

Influence of the Strap Rewind Height During a Conical Pulley Exercise
por: Sabido, Rafael, et al.
Publicado: (2020)

Homecoming: rewinding the reductive evolution of the chloroplast genome for increasing crop yields
por: Llorente, Briardo, et al.
Publicado: (2021)

Rash, disseminated intravascular coagulation and legionella: Episode 10 and a rewind into the past
por: Thalanayar, Prashanth M., et al.
Publicado: (2015)

Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study
por: Torre, Enrico, et al.
Publicado: (2020)

Rewinding the Molecular Clock: Looking at Pioneering Molecular Phylogenetics Experiments in the Light of Proteomics
por: Neely, Benjamin A., et al.
Publicado: (2021)

Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
por: Schnell, Oliver, et al.
Publicado: (2016)

Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
por: Schnell, Oliver, et al.
Publicado: (2018)

Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
por: Schnell, Oliver, et al.
Publicado: (2019)

Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group
por: Schnell, Oliver, et al.
Publicado: (2017)

Correction to: Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group
por: Schnell, Oliver, et al.
Publicado: (2017)

Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial
por: Riddle, Matthew C, et al.
Publicado: (2021)

Real‐world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network
por: Hinton, William, et al.
Publicado: (2019)

GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs
por: Giugliano, Dario, et al.
Publicado: (2021)

Designing Inclusive Systems: Designing Inclusion for Real-world Applications
por: Langdon, Patrick, et al.
Publicado: (2012)

Fragility of cardiovascular outcome trials (CVOTs) examining nutrition interventions among patients with diabetes mellitus: a systematic review of randomized controlled trials
por: Taouktsi, Niki, et al.
Publicado: (2022)

Cardiovascular risk profiles: A cross‐sectional study evaluating the generalizability of the glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN‐6 to the real‐world type 2 diabetes population in the United Kingdom
por: Webb, Joanne, et al.
Publicado: (2021)

SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2021)

Formation of supramolecular channels by reversible unwinding-rewinding of bis(indole) double helix via ion coordination
por: Mondal, Debashis, et al.
Publicado: (2022)

Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis
por: Dagenais, Gilles R., et al.
Publicado: (2020)

RecG and UvsW catalyse robust DNA rewinding critical for stalled DNA replication fork rescue
por: Manosas, Maria, et al.
Publicado: (2013)

Rewinding Extinction in the Northern White Rhinoceros: Genetically Diverse Induced Pluripotent Stem Cell Bank for Genetic Rescue
por: Korody, Marisa L., et al.
Publicado: (2021)

Rewinding the molecular clock in the genus Carabus (Coleoptera: Carabidae) in light of fossil evidence and the Gondwana split: A reanalysis
por: Opgenoorth, Lars, et al.
Publicado: (2021)

The inclusion of real world evidence in clinical development planning
por: Martina, Reynaldo, et al.
Publicado: (2018)

Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials: Perspective on GLP-1 RA and SGLT-2i therapies
por: Ludwig, Lisa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_58e1b9065fmtg9b1uiippmgl58